Mesoblast LTD (MESO)
- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $13.39
- As of
Kresmion compiles this page from MESO's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
MESOBLAST LTD (MESO): 1 institutional manager tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 6-K filed 2026-10-16.
See the full MESO dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for MESO on one page. Preview it with sample data, then open it live with a free account.
Preview the MESO dossierActive events for MESO
- high13F: large increase
CITADEL ADVISORS LLC added +167% to MESO (2026Q2)
- high13F: large increase
CITADEL ADVISORS LLC added +2262% to MESO (2026Q2)
- lowEarnings above estimates
Q3-2023: EPS $-0.0237 vs $-0.0479 estimate, +0.02 on a near-zero consensus
- mediumEarnings above estimates
Q4-2023: Beat consensus by 78.8% - EPS $-0.02655 vs $-0.1252 estimate
- mediumEarnings above estimates
Q2-2026: Beat consensus by 80.1% - EPS $-0.03 vs $-0.1509 estimate
FREE, NO ACCOUNT
Every event on MESO, as it fires
You are seeing 5 of 6 events recorded on MESO since 2026-06-09.
The five above landed across 2 days. The other 1 were recorded on those same days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in MESO (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| TWO SIGMA INVESTMENTS, LPCUSIP 590717401 · 2026Q2 | $587K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, MESO
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 20-FSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
MESO against its peers
MESO's net margin of -593.9% ranks in the 37th percentile of 14 Biotechnology sub-industry peers, fiscal periods ending between 2025-06-30 and 2026-03-31.
| Metric | MESO | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 17.2M USD | 168M USD | 25 | 13 |
| Revenue YoY | 191.4% | n/a | n/a | 0 |
| Gross margin | 70.2% | 93.5% | 8 | 5 |
| Operating margin | n/a | -82.4% | n/a | 14 |
| Net margin | -593.9% | -81.9% | 37 | 14 |
| Return on equity | -17.1% | -59.0% | 83 | 14 |
Peers (19): QURE, NBTX, MAZE, STOK, NVAX, CMPS, RARE, IMCR, URGN, FBRX.D, NTLA, ZBIO, MLYS, REPL, ANAB, TYRA, VIR, ABSI, SRPT. Left out: KLRA (no annual filing), COAG (no annual filing), TRAX (no annual filing), BRVE (no annual filing), GENB (no annual filing), ADRX (no annual filing). Fiscal periods ending between 2025-06-30 and 2026-03-31. Every figure is one full fiscal year read from one annual filing (MESO: 20-F), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Follow MESO on a live board
Kresmion is a cross-asset market-intelligence terminal. Open a board scoped to MESO for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.